- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30437
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
Changes of HBsAg and interferon-inducible protein 10 serum levels
in naive HBeAg-negative chronic hepatitis B patients under 4-year
entecavir therapy
George Papatheodoridis 1,2,⇑, John Goulis 3, Spilios Manolakopoulos 1, Aikaterini Margariti 1,
Xenofon Exarchos 3, Georgios Kokkonis 3, Emilia Hadziyiannis 1, Christos Papaioannou 1,
Emanuel Manesis 4, Dimitrios Pectasides 1, Evangelos Akriviadis 3
1 2nd Department of Internal Medicine, Athens University Medical School, Hippokration Hospital of Athens, Greece;
2 Academic Department
of Gastroenterology, Athens University Medical School, Laikon Hospital of Athens, Greece;
3 4th Department of Medicine,
Aristotelian University of Thessaloniki, Hippokration General Hospital of Thessaloniki, Greece;
4 Athens University Medical School, Greece
Background & Aims: Serum HBsAg levels might represent an
important predictor of sustained off-treatment response in
HBeAg-negative chronic hepatitis B (CHB). We evaluated the
changes of HBsAgand interferon-inducible protein 10 (IP10)serum
levels in HBeAg-negative CHB patients treated with entecavir.
Methods: 114 patients received entecavir for a median of
4.3 years. HBsAg levels were determined at baseline, 6 and
12 months and every year thereafter until year-4. IP10 levels were
measured at baseline and annually until year-4 in 76 patients.
Results: Virological remission rates were high (year-1: 94%, after
year-2: 97–98%). Compared to baseline, HBsAg levels decreased
by a median of 0.03, 0.13, 0.17, 0.22, and 0.32 log10 IU/ml at
6 months and 1, 2, 3, and 4 years, respectively (p 60.001 for all
comparisons). The proportions of patients with HBsAg decline
of P0.5 or P1 log10 IU/ml were 9% or 6% at year-1 and 21% or
10% at the last visit. Median IP10 levels (pg/ml) did not change
from baseline to year-1 or -2 (245 vs. 229 or 251), but increased
at year-3 and -4 (275 and 323, p <0.030). HBsAg drop P0.5 log10
was associated with baseline IP10 or IP10 >350 pg/ml (p 60.002).
HBsAg loss occurred in 4/114 (3.5%) patients or in 1/2, 3/21, and
0/91 patients with baseline HBsAg <100, 100–1000 and >1000 IU/
ml, respectively (p <0.001).
Conclusions: In HBeAg-negative CHB patients, 4-year entecavir
therapy decreases serum HBsAg levels, but the rate of decline is
rather slow. Serum IP10 levels represent a promising predictor
of HBsAg decline in this setting.
|
|